Laboratory and clinical investigations were carried out on cefoxitin (CFX), a semisynthetic ceph.amycin antibiotic, and following results were obtained:
1. CFX exhibited a wide-spectrum growth inhibitory action against Gram-positive cocci and Gramnegative bacilli, and its antibacterial activity was stronger than CET and CER against Escherichia coli, Serratia and Proteus.
2. CFX was injected intravenously by drip infusion singly as a chemotherapeutic drug for the respiratory tract infections, urinary tract infections and gallbladder infection. Favorable results were obtained in 10cases (83. 5%) out of 12 respiratory tract infections and 1 gallbladder infection, while remarkable effect was obtained in 4 cases (80%) out of 5 urinary tract infections.
3. A side effect was observed only in one case, which showed an eosinophilia 2 weeks after the start of CFX administration.
